➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Mallinckrodt
Colorcon
McKinsey
Boehringer Ingelheim

Last Updated: June 3, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MYRBETRIQ

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Myrbetriq

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00410514 A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) Completed Astellas Pharma Inc Phase 2 2006-12-01 This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
NCT00688688 Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Completed Astellas Pharma Inc Phase 3 2008-04-01 The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
NCT00689104 Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Completed Astellas Pharma Inc Phase 3 2008-04-01 The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
NCT01340027 A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder Completed Astellas Pharma Europe B.V. Phase 2 2011-03-01 The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.
NCT01638000 A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. Completed Astellas Pharma Europe Ltd. Phase 3 2012-06-01 The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of efficacy.
NCT01908829 A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) Completed Astellas Pharma Europe Ltd. Phase 3 2013-07-01 The purpose of this study is to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) will be more effective in controlling incontinence than when using the antimuscarinic treatment alone.
NCT01972841 This is a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder Completed Astellas Pharma Europe B.V. Phase 3 2013-11-01 The purpose of this study is to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Myrbetriq

Condition Name

Condition Name for Myrbetriq
Intervention Trials
Overactive Bladder 12
Urinary Bladder, Overactive 5
Lower Urinary Tract Symptoms 4
Urinary Bladder Overactive 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Myrbetriq
Intervention Trials
Urinary Bladder, Overactive 19
Urologic Diseases 6
Urinary Bladder Diseases 6
Lower Urinary Tract Symptoms 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Myrbetriq

Trials by Country

Trials by Country for Myrbetriq
Location Trials
United States 189
Canada 37
Denmark 9
Germany 9
Poland 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Myrbetriq
Location Trials
New York 9
California 8
Massachusetts 8
Florida 8
Pennsylvania 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Myrbetriq

Clinical Trial Phase

Clinical Trial Phase for Myrbetriq
Clinical Trial Phase Trials
Phase 4 9
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Myrbetriq
Clinical Trial Phase Trials
Completed 14
Recruiting 12
Not yet recruiting 9
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Myrbetriq

Sponsor Name

Sponsor Name for Myrbetriq
Sponsor Trials
Astellas Pharma Europe B.V. 7
Astellas Pharma Inc 6
Astellas Pharma Global Development, Inc. 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Myrbetriq
Sponsor Trials
Other 23
Industry 23
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Express Scripts
AstraZeneca
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.